Objective: To explore the current situation of pharmacovigilance system construction in the European

Union, the United States, South Korea, Japan, and China, and to provide suggestions and references for the

construction of pharmacovigilance system in medical agencies in China. Methods: The current situation of

pharmacovigilance system construction in the European Union, the United States, South Korea, and Japan was

analyzed, and the construction of pharmacovigilance system in medical agencies in China was compared with that.

The suggestions for pharmacovigilance construction in medical agencies in China were put forward. Results and

Conclusion: Pharmacovigilance is an important aspect of drug safety supervision, which runs through the entire

lifecycle of drugs. China should fully utilize the advantages of the main reporting channel of medical agencies,

establish a pharmacovigilance system of medical agencies with Chinese characteristics, and strengthen risk

monitoring and early warning to promote safe use of drugs in clinical settings.